9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2018-10, Vol.29, p.viii705-viii705 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | viii705 |
|---|---|
| container_issue | |
| container_start_page | viii705 |
| container_title | Annals of oncology |
| container_volume | 29 |
| creator | Conte, P.F. Guarneri, V. Bisagni, G. Piacentini, F. Brandes, A.A. Cavanna, L. Giotta, F. Aieta, M. Gebbia, V. Frassoldati, A. Musolino, A. Garrone, O. Taverniti, C. Rimanti, A. Sarti, S. Rubino, D. Bologna, A. Vicini, R. Balduzzi, S. D'Amico, R. |
| description | |
| doi_str_mv | 10.1093/annonc/mdy424.005 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdy424_005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419503969</els_id><sourcerecordid>32137961</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2785-b1a8d0e59dadceba28f3f708c58cd4ba75764670ed8780131924cd86d7badcae3</originalsourceid><addsrcrecordid>eNp9kc1u1DAURi0EotPCA7BBd4_SsfMfWKGqpUiVkCiso2v7hnGb2CPbySg8Lw-C2ylIbFjZsr_z-cqHsTeCnwveFVu01lm1nfRa5uU559UzthFV3WUtL8VztuFdXmRNVZQn7DSEO8553eXdS3ZS5KJoulps2K8ODkT3ARbyYQ4gYCX0gPpuXtBGiB5DnH_OE0oYnIfry6_5O0iRcQXpKV2CQqvIv4fbWf7wbt4DWhzXYAK4AeKO4HbnfExgKjM4Ao6jOwSIDowmG82wwh6jSdvw-MRh5yZACA8U-X8mQD0Za0I6isZZmHCFHS6U0gMubvYoRwJvwv1WkqXBRHhMvmIvBhwDvX5az9j3q8tvF9fZzZdPny8-3mQqb9oqkwJbzanqNGpFEvN2KIaGt6pqlS4lNlVTl3XDSbdNy0UhurxUuq11IxOAVJwxcexV3oXgaej33kzo117w_sFYfzTWH431yVhi3h6Z_Swn0n-JP4pS4MMxQGnyxZDvg0qfpUgbTyr22pn_1P8GM92wRQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Conte, P.F. ; Guarneri, V. ; Bisagni, G. ; Piacentini, F. ; Brandes, A.A. ; Cavanna, L. ; Giotta, F. ; Aieta, M. ; Gebbia, V. ; Frassoldati, A. ; Musolino, A. ; Garrone, O. ; Taverniti, C. ; Rimanti, A. ; Sarti, S. ; Rubino, D. ; Bologna, A. ; Vicini, R. ; Balduzzi, S. ; D'Amico, R.</creator><creatorcontrib>Conte, P.F. ; Guarneri, V. ; Bisagni, G. ; Piacentini, F. ; Brandes, A.A. ; Cavanna, L. ; Giotta, F. ; Aieta, M. ; Gebbia, V. ; Frassoldati, A. ; Musolino, A. ; Garrone, O. ; Taverniti, C. ; Rimanti, A. ; Sarti, S. ; Rubino, D. ; Bologna, A. ; Vicini, R. ; Balduzzi, S. ; D'Amico, R.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdy424.005</identifier><identifier>PMID: 32137961</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><ispartof>Annals of oncology, 2018-10, Vol.29, p.viii705-viii705</ispartof><rights>2018 THE AUTHORS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2785-b1a8d0e59dadceba28f3f708c58cd4ba75764670ed8780131924cd86d7badcae3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32137961$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Conte, P.F.</creatorcontrib><creatorcontrib>Guarneri, V.</creatorcontrib><creatorcontrib>Bisagni, G.</creatorcontrib><creatorcontrib>Piacentini, F.</creatorcontrib><creatorcontrib>Brandes, A.A.</creatorcontrib><creatorcontrib>Cavanna, L.</creatorcontrib><creatorcontrib>Giotta, F.</creatorcontrib><creatorcontrib>Aieta, M.</creatorcontrib><creatorcontrib>Gebbia, V.</creatorcontrib><creatorcontrib>Frassoldati, A.</creatorcontrib><creatorcontrib>Musolino, A.</creatorcontrib><creatorcontrib>Garrone, O.</creatorcontrib><creatorcontrib>Taverniti, C.</creatorcontrib><creatorcontrib>Rimanti, A.</creatorcontrib><creatorcontrib>Sarti, S.</creatorcontrib><creatorcontrib>Rubino, D.</creatorcontrib><creatorcontrib>Bologna, A.</creatorcontrib><creatorcontrib>Vicini, R.</creatorcontrib><creatorcontrib>Balduzzi, S.</creatorcontrib><creatorcontrib>D'Amico, R.</creatorcontrib><title>9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1DAURi0EotPCA7BBd4_SsfMfWKGqpUiVkCiso2v7hnGb2CPbySg8Lw-C2ylIbFjZsr_z-cqHsTeCnwveFVu01lm1nfRa5uU559UzthFV3WUtL8VztuFdXmRNVZQn7DSEO8553eXdS3ZS5KJoulps2K8ODkT3ARbyYQ4gYCX0gPpuXtBGiB5DnH_OE0oYnIfry6_5O0iRcQXpKV2CQqvIv4fbWf7wbt4DWhzXYAK4AeKO4HbnfExgKjM4Ao6jOwSIDowmG82wwh6jSdvw-MRh5yZACA8U-X8mQD0Za0I6isZZmHCFHS6U0gMubvYoRwJvwv1WkqXBRHhMvmIvBhwDvX5az9j3q8tvF9fZzZdPny8-3mQqb9oqkwJbzanqNGpFEvN2KIaGt6pqlS4lNlVTl3XDSbdNy0UhurxUuq11IxOAVJwxcexV3oXgaej33kzo117w_sFYfzTWH431yVhi3h6Z_Swn0n-JP4pS4MMxQGnyxZDvg0qfpUgbTyr22pn_1P8GM92wRQ</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Conte, P.F.</creator><creator>Guarneri, V.</creator><creator>Bisagni, G.</creator><creator>Piacentini, F.</creator><creator>Brandes, A.A.</creator><creator>Cavanna, L.</creator><creator>Giotta, F.</creator><creator>Aieta, M.</creator><creator>Gebbia, V.</creator><creator>Frassoldati, A.</creator><creator>Musolino, A.</creator><creator>Garrone, O.</creator><creator>Taverniti, C.</creator><creator>Rimanti, A.</creator><creator>Sarti, S.</creator><creator>Rubino, D.</creator><creator>Bologna, A.</creator><creator>Vicini, R.</creator><creator>Balduzzi, S.</creator><creator>D'Amico, R.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201810</creationdate><title>9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio</title><author>Conte, P.F. ; Guarneri, V. ; Bisagni, G. ; Piacentini, F. ; Brandes, A.A. ; Cavanna, L. ; Giotta, F. ; Aieta, M. ; Gebbia, V. ; Frassoldati, A. ; Musolino, A. ; Garrone, O. ; Taverniti, C. ; Rimanti, A. ; Sarti, S. ; Rubino, D. ; Bologna, A. ; Vicini, R. ; Balduzzi, S. ; D'Amico, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2785-b1a8d0e59dadceba28f3f708c58cd4ba75764670ed8780131924cd86d7badcae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Conte, P.F.</creatorcontrib><creatorcontrib>Guarneri, V.</creatorcontrib><creatorcontrib>Bisagni, G.</creatorcontrib><creatorcontrib>Piacentini, F.</creatorcontrib><creatorcontrib>Brandes, A.A.</creatorcontrib><creatorcontrib>Cavanna, L.</creatorcontrib><creatorcontrib>Giotta, F.</creatorcontrib><creatorcontrib>Aieta, M.</creatorcontrib><creatorcontrib>Gebbia, V.</creatorcontrib><creatorcontrib>Frassoldati, A.</creatorcontrib><creatorcontrib>Musolino, A.</creatorcontrib><creatorcontrib>Garrone, O.</creatorcontrib><creatorcontrib>Taverniti, C.</creatorcontrib><creatorcontrib>Rimanti, A.</creatorcontrib><creatorcontrib>Sarti, S.</creatorcontrib><creatorcontrib>Rubino, D.</creatorcontrib><creatorcontrib>Bologna, A.</creatorcontrib><creatorcontrib>Vicini, R.</creatorcontrib><creatorcontrib>Balduzzi, S.</creatorcontrib><creatorcontrib>D'Amico, R.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Conte, P.F.</au><au>Guarneri, V.</au><au>Bisagni, G.</au><au>Piacentini, F.</au><au>Brandes, A.A.</au><au>Cavanna, L.</au><au>Giotta, F.</au><au>Aieta, M.</au><au>Gebbia, V.</au><au>Frassoldati, A.</au><au>Musolino, A.</au><au>Garrone, O.</au><au>Taverniti, C.</au><au>Rimanti, A.</au><au>Sarti, S.</au><au>Rubino, D.</au><au>Bologna, A.</au><au>Vicini, R.</au><au>Balduzzi, S.</au><au>D'Amico, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2018-10</date><risdate>2018</risdate><volume>29</volume><spage>viii705</spage><epage>viii705</epage><pages>viii705-viii705</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32137961</pmid><doi>10.1093/annonc/mdy424.005</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2018-10, Vol.29, p.viii705-viii705 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdy424_005 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T07%3A55%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=9%20weeks%20versus%201%20year%20adjuvant%20trastuzumab%20for%20HER2+%20early%20breast%20cancer:%20Subgroup%20analysis%20of%20the%20ShortHER%20trial%20allows%20to%20identify%20patients%20for%20whom%20a%20shorter%20trastuzumab%20administration%20may%20have%20a%20favourable%20risk/benefit%20ratio&rft.jtitle=Annals%20of%20oncology&rft.au=Conte,%20P.F.&rft.date=2018-10&rft.volume=29&rft.spage=viii705&rft.epage=viii705&rft.pages=viii705-viii705&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdy424.005&rft_dat=%3Cpubmed_cross%3E32137961%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32137961&rft_els_id=S0923753419503969&rfr_iscdi=true |